Genesis Biopharma to establish Adoptive Cell Immunotherapy based therapeutic development program

Mar 16 2011

Genesis Biopharma, Inc. (OTC Bulletin Board: GNBP), a biotechnology company developing targeted cancer therapies, today announced it is expanding its therapeutic strategy to include active immunotherapies to treat various cancers.  The Company will focus on establishing a therapeutic development program based on Adoptive Cell Immunotherapy.  The new strategy will be discussed during a presentation today at the Roth Capital Growth Stock Conference in Laguna Niguel, California.

"Adoptive Cell Immunotherapy, which utilizes cells from a patient's own immune system to treat cancer, is one of the most promising areas of oncology," said Anthony J. Cataldo, President and Chief Executive Officer. "The strategy to develop active immunotherapies complements our current passive immunotherapy platform based on GBP-102, our Anti-CD55+ therapeutic antibody candidate," stated Mr. Cataldo.

"Presently we are working to bring together the necessary intellectual property and technology assets, along with the scientific and manufacturing expertise to build out a commercial-scale Adoptive Cell Immunotherapy program," said Mr. Cataldo.